P04.07: Investigating Key Host, Microbial and Variant Peptides for DETECTION OF ORAL CANCER USING ADVANCED MULTI-OMICS METHODS.

Pratik Jagtap¹, Ruben Shrestha², Beverly Wuertz³, Monica Kruk⁴, Subina Mehta¹, Alvaro Sebastian Vaca Jacome², Matt Willetts⁴, Frank Ondrey³, Timothy Griffin¹ ¹Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, USA; ²Bruker Scientific LLC, San Jose, CA; ³Otolaryngology Department, University of Minnesota, Minneapolis, Minnesota; ⁴Bruker Scientific, LLC, Billerica, MA

There is an unmet need for risk stratification biomarkers for precancerous oral leukoplakia patients. While host biomarkers are available for detection, there is a clear need to expand the biomarker panel to improve predictive performance. We have used the latest methods for enrichment of lowabundance proteins from non-invasively collected samples, sensitive mass spectrometry (MS) methods, and advanced bioinformatic analysis to delve deeper into host, variant and microbial proteome from precancerous patients.


METHODS: Oral rinse samples from six oral precancerous lesion patients (pre/post chemoprevention agent treatment) were processed using the PreOmics ENRICH kit to facilitate the detection of low abundance proteins. Digested proteins were analyzed by DIA-PASEF on a hybrid TIMS QTOF mass spectrometer (Bruker). 16S rRNA analysis and RNASeq analysis was used to generate a customized proteogenomics and metaproteomics database. The MS data was searched against the human proteome along with variant proteins and microbial proteins using Spectronaut (Biognosys). Bioinformatic and statistical analysis was performed to detect differentially expressed host proteins, microbial proteins and novel proteoforms. **EXPERIMENTAL WORKFLOW: ORAL LEUKOPLAKIA ORAL LESION** 90-DAYS OF PIOGLITAZONE PRE-TREATMENT **TREATMENT** SAMPLES -**ORAL RINSE SAMPLES** PO **Enrichment** BRUKER Mass spectrometry using DIA-PASEF **Search against Human + Microbiome + Novel Proteoforms** DATABASE SEARCH RESULTS: 11000 Human Proteins Microbial Proteins Variant Proteins 6291 2029 **5278** 5151 5031 4332 4156 Human dB + PG Human dB + **Human dB** SalivaryMP 16S rRNA sps **3framedB** RNASeq DB (82,283 protein

(914,388 protein (503,892 protein (620,033 protein (109,757 protein

sequences)

sequences)

Sequences)



- Several human, microbial and variant proteins were detected to be differentially abundant in pretreatment and treated samples.
- Pathways such as Gamma-carboxylation of protein precursors and complement cascade were upregulated and Vesicle-mediated transport and inflammasome pathways were downregulated after
- treatment.
- Microbial functions associated with glucosyltransferase activity were upregulated and oxidative stress functions were downregulated after treatment.
- Variant proteins and peptides associated with PYCARD and GDI2 are upregulated after treatment.
- Peptides associated with differentially abundant human, microbial and variant proteins will be used for targeted analysis.